VRDN - Viridian Therapeutics, Inc.\DE

QQQ $ 610.16 $ 0.00 (0 %)

DIA $ 468.92 $ 0.00 (0 %)

SPY $ 671.13 $ 0.00 (0 %)

TLT $ 92.08 $ 0.00 (0 %)

GLD $ 374.35 $ 0.00 (0 %)

Previous Close

$ 24.02

Open

$ 24.65

Bid

$ 22.05 x 100

Ask

$ 23.80 x 100

Day's Range

-- - --

52 Week Range

$ 9.90 - $ 27.20

Volume

782,377

Average Volume

Market Cap

1.96B

Beta (5Y Monthly)

$ 0.07

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	03-03-2025	01-01-1970	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-27-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-10-2023	03-31-2023	10-Q
11	03-09-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-13-2022	03-31-2022	10-Q
15	03-11-2022	12-31-2021	10-K
16	11-05-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-07-2021	03-31-2021	10-Q
19	03-26-2021	12-31-2020	10-K
20	11-12-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	05-08-2020	03-31-2020	10-Q
23	03-13-2020	12-31-2019	10-K
24	11-08-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	03-14-2019	12-31-2018	10-K
28	11-07-2018	09-30-2018	10-Q
29	08-08-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-15-2018	12-31-2017	10-K
32	11-09-2017	09-30-2017	10-Q
33	08-11-2017	06-30-2017	10-Q
34	05-11-2017	03-31-2017	10-Q
35	03-24-2017	12-31-2016	10-K
36	10-26-2016	09-30-2016	10-Q
37	08-15-2016	06-30-2016	10-Q
38	05-16-2016	03-31-2016	10-Q
39	03-21-2016	12-31-2015	10-K
40	11-13-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Reported Earlier, Viridian Therapeutics Pr...
10/22/2025 07:26:19

Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together wit...

Viridian Therapeutics Launches An Underwri...
10/21/2025 20:03:23

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing poten...

Expert Outlook: Viridian Therapeutics Thro...
10/21/2025 20:00:39

DRI Healthcare Trust Acquires Royalty Inte...
10/20/2025 11:34:52

10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

these-analysts-revise-their-forecasts-on-viridian-therapeutics-following-q2-results

These Analysts Revise Their Forecasts On V...
08/07/2025 18:37:46

Goldman Sachs Maintains Buy on Viridian Th...
08/07/2025 17:53:04

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...

RBC Capital Maintains Outperform on Viridi...
08/07/2025 15:34:16

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target ...

Wells Fargo Maintains Equal-Weight on Viri...
08/07/2025 14:36:11

Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Equal-Weight and lowers the price tar...

Oppenheimer Maintains Outperform on Viridi...
08/07/2025 13:31:02

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price tar...

Needham Maintains Buy on Viridian Therapeu...
08/06/2025 18:07:34

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36...

Viridian Therapeutics Q2 EPS $(1.00) Beats...
08/06/2025 11:56:16

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...

Viridian Therapeutics Signs $70M Upfront L...
07/30/2025 08:21:56

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -Viridian to receive an upfro...

Needham Reiterates Buy on Viridian Therape...
05/20/2025 15:23:44

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $36 price target.

Viridian Therapeutics Announces Positive L...
05/20/2025 11:06:11

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week ...

What 5 Analyst Ratings Have To Say About V...
05/07/2025 22:00:53

Viridian Therapeutics Receives FDA Breakth...
05/07/2025 20:16:29

- Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of di...

RBC Capital Maintains Outperform on Viridi...
05/07/2025 17:50:09

RBC Capital analyst Michael Carroll maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price tar...

Goldman Sachs Maintains Buy on Viridian Th...
05/07/2025 17:11:48

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from ...

JMP Securities Maintains Market Outperform...
05/07/2025 16:44:45

JMP Securities analyst Jason Butler maintains Viridian Therapeutics (NASDAQ:VRDN) with a Market Outperform and lowers the pr...